Abstract Medulloblastoma is the most common malignant pediatric brain tumor. Tumors are typically characterized as Group 3, 4, SHH, or WNT. Current standard-of-care includes surgery, radiation, and chemotherapy; however, treatment response prognosis vary widely between subgroups. Additionally, surviving children frequently suffer from lifelong neurocognitive deficits. Therefore, novel therapeut...